1.Mechanism of Shexiang Tongxin Dripping Pills in Ameliorating AngⅡ-induced Vascular Smooth Muscle Cell Dysfunction
Yueyao HU ; Wei WANG ; Mingyue HUANG ; Shujuan GUO ; Junkai YAO
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(8):97-106
ObjectiveTo study the mechanism of Shexiang Tongxin Dripping pills-containing serum (STDP) in ameliorating angiotensinⅡ (AngⅡ)-induced cell phenotype transformation, proliferation, migration, and dysfunction of vascular smooth muscle cells. MethodsAn AngⅡ-induced proliferation and migration model of vascular smooth muscle cells was established. The cells were treated with STDP at 5%, 10%, and 20% for 24 h. The immunofluorescence assay was employed to detect the expression of α smooth muscle actin (α-SMA) and matrix metalloproteinase-2 (MMP-2). The cell-counting kit-8 (CCK-8) assay and 5-ethynyl-2'-deoxyuridine (EdU) staining were employed to detect the proliferation of vascular smooth muscle cells, and the scratch assay was employed to detect the migration of the cells. Western blot was employed to determine the expression levels of pathway proteins such as angiotensin-converting enzyme 2 (ACE2), angiotensin Ⅱ type 2 (AT2), angiotensin Ⅱ type 1 (AT1), as well as proliferation and migration proteins such as typeⅠ collagen (ColⅠ) and osteopontin (OPN). ResultsCompared with the model group, STDP increased the expression of α-SMA, reduced the expression of MMP-2, and inhibited the proliferation and migration of vascular smooth muscle cells (P<0.05). Furthermore, STDP up-regulated the expression levels of ACE2, AT2, and MAS1, while down-regulating the expression level of AT1, PCNA, ColⅠ, MMP-9, Rock1, Rock2, and SRF (P<0.05). Compared with the STDP group, the ACE2 inhibitor reversed the regulatory effects of STDP. ConclusionSTDP inhibits the phenotype transformation, proliferation, and migration of vascular smooth muscle cells and regulates the expression of cell proliferation and migration-related proteins to ameliorate the dysfunction of vascular smooth muscle cells. It exerts the effects by up-regulating the expression of proteins in the ACE2-AT2/MAS pathway and down-regulating the expression of proteins in the AT1-Rock signaling pathway.
2.Randomized Controlled Trials on Chinese Herbal Medicine Therapy for Atopic Dermatitis: An Evidence Map
Mingyue LIU ; Baixiang HE ; Jingqiu HU ; Youran DAI ; Lingling REN ; Shufan GE ; Kelin LI ; Qiubai JIN ; Ping SONG ; Huiyan CHI
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(21):138-145
ObjectiveTo characterize the evidence distribution and methodological quality of randomized controlled trials (RCTs) on oral Chinese herbal medicine (CHM) for atopic dermatitis (AD) based on evidence mapping. MethodsSeven databases (CNKI, Wanfang Data, VIP, CBM, Cochrane Library, PubMed, and Embase) and the Chinese Clinical Trial Registry were searched for the RCTs in Chinese and English. Evidence distribution was presented graphically and textually, and methodological quality was assessed via the Cochrane Risk of Bias tool (ROB 1.0). ResultsA total of 168 RCTs were included. The number of annual publications showing an increasing trend, and 72.6% RCTs had sample sizes of 51-100 participants. The studies evaluated 108 distinct CHM interventions categorized as decoctions, granules, Chinese patent medicines, and extracts. Compound Glycyrrhizin was the most frequently used, followed by Xiaofengsan and Chushi Weiling decoction. Among the RCTs, 57.1% had the treatment courses of 4-8 weeks. Outcome measures predominantly focused on clinical response rate, skin lesion severity scores, and adverse events, with less attention to TCM symptom scores, skin barrier function, and relapse rates. The overall risk of bias was generally high. ConclusionWhile CHM for AD is a research hotspot and demonstrates clinical advantages, the related studies have problems such as unclear clinical positioning, poor research standardization and methodological quality, and insufficient prominence of TCM clinical advantages. Large-sample, methodologically rigorous, and high-quality studies are needed to enhance the evidence base for CHM in treating AD.
3.Randomized Controlled Trials on Chinese Herbal Medicine Therapy for Atopic Dermatitis: An Evidence Map
Mingyue LIU ; Baixiang HE ; Jingqiu HU ; Youran DAI ; Lingling REN ; Shufan GE ; Kelin LI ; Qiubai JIN ; Ping SONG ; Huiyan CHI
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(21):138-145
ObjectiveTo characterize the evidence distribution and methodological quality of randomized controlled trials (RCTs) on oral Chinese herbal medicine (CHM) for atopic dermatitis (AD) based on evidence mapping. MethodsSeven databases (CNKI, Wanfang Data, VIP, CBM, Cochrane Library, PubMed, and Embase) and the Chinese Clinical Trial Registry were searched for the RCTs in Chinese and English. Evidence distribution was presented graphically and textually, and methodological quality was assessed via the Cochrane Risk of Bias tool (ROB 1.0). ResultsA total of 168 RCTs were included. The number of annual publications showing an increasing trend, and 72.6% RCTs had sample sizes of 51-100 participants. The studies evaluated 108 distinct CHM interventions categorized as decoctions, granules, Chinese patent medicines, and extracts. Compound Glycyrrhizin was the most frequently used, followed by Xiaofengsan and Chushi Weiling decoction. Among the RCTs, 57.1% had the treatment courses of 4-8 weeks. Outcome measures predominantly focused on clinical response rate, skin lesion severity scores, and adverse events, with less attention to TCM symptom scores, skin barrier function, and relapse rates. The overall risk of bias was generally high. ConclusionWhile CHM for AD is a research hotspot and demonstrates clinical advantages, the related studies have problems such as unclear clinical positioning, poor research standardization and methodological quality, and insufficient prominence of TCM clinical advantages. Large-sample, methodologically rigorous, and high-quality studies are needed to enhance the evidence base for CHM in treating AD.
4.Sequence analysis of whole genome of influenza A(H3N2) virus in Huai′an
Pengfei YANG ; Fang HE ; Wanli YIN ; Tong GAO ; Wang ZHANG ; Mingyue WEI ; Chenglong XIONG ; Wei HU
Chinese Journal of Experimental and Clinical Virology 2024;38(2):156-161
Objective:To study the biological traits and mutations of the influenza A (H3N2) virus in order to produce a vaccine and offer references for controlling and preventing influenza epidemics.Methods:Four strains of the influenza A(H3N2) virus were chosen from the Huai′an surveillance network laboratory. Nucleic acid extraction, library building, and sequencing (CridION x5 MKI Nanopore) were used to produce the whole-genome sequences. Using homologous alignments of whole-genome sequences, phylogenetic tree construction, and amino acid variant screening, bioinformatics analysis was carried out.Results:The nucleotide identity between 8 gene segments ranged from 97.1% to 100.0%. The gene that differed the most from the reference sequences was HA (97.1%-99.9%), and the gene that differed the least was MP (98.6%-99.9%). The HA gene (3.06%) and MP gene (1.43%) were the regions with the greatest and lowest frequencies of nucleotide site change, respectively. The rates of nucleotide change varied significantly between the genes ( χ2=14.293, P=0.046). Four influenza A(H3N2) virus strains′ whole-genome phylogenies from each of the eight gene segments maintained a roughly consistent topological structure. One strain was linked to the 3C.2a1b.1b clade, which was lost at the 142NWT, 149NGT(HA1), and 436NLS(NA). Three strains were linked to the 3C.2a1b.2a.1a clade lineage. Amantadine and NA inhibitors were effective against all Huai′an strains. Conclusions:The antigenicity of one strain of Huai'an strain changed and its matching with the vaccine strain of that year was low. It is suggested that the genetic surveillance of H3N2 influenza virus should be continuously strengthened to provide scientific basis for influenza prevention and control and influenza vaccine screening.
5.Dupilumab combined with minocycline or with minocycline and systemic glucocorticoids for the treatment of bullous pemphigoid: a cohort study
Junyu HU ; Danyang CHEN ; Xixue CHEN ; Mingyue WANG
Chinese Journal of Dermatology 2024;57(10):917-924
Objective:To compare the efficacy, dosage, and safety of dupilumab combined with minocycline or with minocycline and systemic glucocorticoids (sGC) versus minocycline alone or in combination with sGC in patients with bullous pemphigoid (BP) .Methods:A retrospective cohort study was conducted on BP patients who visited the Department of Dermatology, Peking University First Hospital from March 2021 to June 2022 and were treated with one of the following two therapeutic regimens: minocycline alone or in combination with sGC (M-MG group), and dupilumab combined with minocycline or with minocycline and sGC (MD-MGD group). Disease control rates, time to disease control, complete remission rates, time to complete remission, BP disease area index (BPDAI) scores, drug usage, time to pruritus relief, relapse rates, and occurrence rates of adverse reactions were compared between the two groups. Survival analysis was performed using Kaplan-Meier (KM) curves and Log-rank test. Confounders were controlled by 1∶1 matching on the propensity score in the two groups.Results:A total of 164 patients were collected, including 110 in the M-MG group (62 males and 48 females, aged 74.6 ± 12.8 years) and 54 in the MD-MGD group (33 males and 21 females, aged 74.6 ± 13.3 years). After two-week follow-up, there was no significant difference in the disease control rate between the two groups ( P = 0.341); however, the minocycline dose, proportion of patients using sGC, sGC dose, and cumulative sGC dose were all significantly higher in the M-MG group than in the MD-MGD group (all P < 0.05). A total of 152 patients (92.7%) achieved disease control in the two groups during the follow-up, while the disease control rate and time to disease control did not differ between the two groups (both P > 0.05); 52 patients (31.7%) achieved complete remission, there was no significant difference in the complete remission rate between the MD-MGD group (16/54, 29.6%) and M-MG group (36/110, 32.7%; χ2 = 0.16, P = 0.689), but the time to complete remission ( M[ Q1, Q3]) was significantly shorter in the MD-MGD group (98.5[78.0, 185.2] days) than in the M-MG group (223.5 [175.2, 277.0] days, P = 0.001). KM survival curve analysis showed that the cumulative complete remission rate was significantly higher in the MD-MGD group than in the M-MG group ( P = 0.024). A total of 73 patients (44.5%) recorded the time to pruritus relief during the follow-up, and the MD-MGD group showed significantly shorter time to pruritus relief (54 patients, 14.0 [3.0, 14.0] days) compared with the M-MG group (19 patients, 14.0 [7.0, 19.0] days; P = 0.015). After propensity score matching, each group included 42 patients; during the follow-up, there was no significant difference in the complete remission rate between the M-MG group and MD-MGD group ( P > 0.05), but the time to complete remission was significantly longer in the M-MG group than in the MD-MGD group ( P = 0.019); KM survival curve analysis showed that the cumulative complete remission rate was significantly higher in the MD-MGD group than in the M-MG group ( P = 0.041). Among the 164 patients, adverse reactions occurred in 58 (35.4%), grade 3 or more severe adverse reactions occurred in 11 (6.70%), but no dupilumab-related adverse reactions were reported. Conclusions:Compared with minocycline alone or in combination with sGC in the treatment of BP, the dupilumab combination therapy could relieve pruritus and result in complete remission in a shorter time. Additionally, dupilumab could help to accelerate the reduction in dosages of sGC and minocycline, with few adverse reactions and favorable safety.
6.Predictive analysis of 25-(OH)D3,IGF-1 and complement C3 on progression in children patients with Henoch-Sch?nlein purpura
Jianqiang SHEN ; Yueyuan HU ; Mingyue SUN ; Lei YANG
Chongqing Medicine 2024;53(22):3396-3400
Objective To analyze the expression levels of 25-hydroxyvitamin D3[25-(OH)D3],insulin-like growth factor 1(IGF-1)and complement C3 in children patients with Henoch-Sch?nlein purpura(HSP)and their predictive efficiency on disease progression.Methods A total of 102 children patients with HSP ad-mitted and treated in this hospital from June 2018 to June 2023 were selected as the study subjects and includ-ed in the observation group.They were divided into the mild group(35 cases),moderate group(41 cases)and severe group(26 cases)according to the severity degree.Additionally,50 healthy children undergoing physical examination during the same period served as the control group.The differences in serum 25-(OH)D3,IGF-1 and complement C3 levels were compared among the groups,as well as their correlations with the disease se-verity.Logistic regression analysis was used to determine the influencing factors of disease progression in chil-dren patients with HSP,and the value of 25-(OH)D3,IGF-1 and complement C3 in predicting disease progres-sion was assessed by using the receiver operating characteristic(ROC)curve.Results The levels of 25-(OH)D3 and C3 in the observation group were lower than those in the control group,while the level of IGF-1 was higher than that in the control group(P<0.05).The levels of 25-(OH)D3 and C3 in the severe group were lower than those in the mild group and moderate group,moreover the moderate group was lower than the mild group(P<0.05).The level of IGF-1 in the severe group was higher than that in the mild group and moderate group,moreover the moderate group was higher than the mild group(P<0.05).The Spearman correlation a-nalysis results indicated that the levels of 25-(OH)D3 and complement C3 were negatively correlated with dis-ease severity(r=-0.375,-0.576,P<0.05),while the level of IGF-1 was positively correlated with the dis-ease severity(r=0.866,P<0.05).The ROC curve analysis results revealed that the area under the curve(AUC)of the combined detection of 25-(OH)D3,complement C3 and IGF-1 for predicting the disease pro-gression was the maximal(0.888),the sensitivity was 81.4%,the specificity was 82.0%and the Youden in-dex was 0.634.Conclusion 25-(OH)D3,IGF-1 and complement C3 have the higher sensitivity and specificity in comprehensively assessing the disease progression of children patients with HSP,and possess the higher clinical value on the risk evaluation of the disease progress in the children patients with HSP.
7.Research progress of mTOR regulating T cell proliferation and function
Han WU ; Hong HUANG ; Ouyang YI ; Mingyue HU ; Liang LIU ; Xiong CAI
Chinese Journal of Immunology 2024;40(9):1992-2000
The mechanistic target of rapamycin(mTOR)plays a pivotal role in various cellular processes,including growth,proliferation and differentiation.As an essential component of the human immune system,T lymphocytes are regulated by mTOR through metabolic pathways such as carbohydrate metabolism and lipid metabolism.This article summarizes the critical role of mTOR in T cell differentiation and reviews recent advances in natural compounds that modulate T cells via mTOR.These findings contribute to the development of mTOR-targeted therapies for diseases.
8.Construction of the evaluation index system for long-term care needs of community-dwelling elderly based on International Classification of Functioning, Disability and Health
Hengyu HU ; Mingyue HU ; Panpan CUI ; Junmei ZHANG ; Hui FENG
Chinese Journal of Modern Nursing 2024;30(22):2984-2991
Objective:To construct an evaluation index system for the long-term care needs of community-dwelling elderly.Methods:Based on the International Classification of Functioning, Disability and Health, a preliminary evaluation index system was formed using literature research and descriptive research. The evaluation index system was revised and improved through the expert consultation.Results:Two rounds of consultation were conducted on 20 experts. The effective response rates of the questionnaire for two rounds of expert consultation were 90.0% (18/20) and 94.4% (17/18), respectively. The expert opinion submission rates were 94.4% (17/18) and 29.4% (5/17), and the expert authority coefficients were 0.94 and 0.95, respectively. After two rounds of expert consultation, the coefficient of variation of each indicator was less than 0.15, and the Kendall harmony coefficients of the overall indicator and all levels of indicators were 0.277 to 0.441 (all P<0.01). The final evaluation index system consisted of three first-level indicators, 12 second-level indicators, and 49 third-level indicators. Conclusions:The construction process of the evaluation index system established is rigorous, the content is comprehensive, and the research methods and results are scientific and reliable. It can provide a basis for further developing long-term care needs assessment tools for community-dwelling elderly and establishing grading standards for long-term care needs assessment.
9.Study on the clinical comprehensive evaluation of blood lipid-regulating drugs in five provinces and regions in Northwest China
Yuan QIAO ; Hang ZHAO ; Jiaxi DU ; Jingyi MAN ; Sen XU ; Fangyi MA ; Shuchen HU ; Jin PENG ; Minghuan JIANG ; Mingyue ZHAO ; Yu FANG
China Pharmacy 2023;34(10):1165-1171
OBJECTIVE To explore standardized evaluation process for clinical comprehensive evaluation of blood lipid- regulating drugs and perform rapid assessment of clinical comprehensive evaluation of blood lipid-regulating drugs with different mechanisms so as to provide reference for the drug catalogue selection and rational drug use of medical institutions. METHODS Referring to guidelines and consensus such as the guideline for the management of comprehensive clinical evaluation of drugs, the methods such as literature research, expert interviews, and Delphi expert consultation were used to establish a multi-dimensional and multi-criteria clinical comprehensive evaluation index system and quantitative scoring table for blood lipid-regulating drugs around the two main lines of technical evaluation and policy evaluation. Then 13 blood lipid-regulating drugs with different mechanisms in 21 third-grade class-A medical institutions from five provinces and regions of Northwest China were scored from both technical and policy dimensions to form a comprehensive evaluation result. RESULTS The clinical comprehensive evaluation index system and corresponding rapid evaluation quantitative scoring table were constructed for blood lipid-regulating drugs in the five northwest provinces and regions. The technicalevaluation section included 6 primary indicators, 13 secondary indicators, and 34 tertiary indicators, totaling 110 points. The policy evaluation section included 4 primary indicators and 6 secondary indicators, with a total score of 40 points (30 points for some drugs) and a total score of 150 points (or 140 points). The scoring results showed that the highest score was atorvastatin, followed by rosuvastatin and simvastatin. CONCLUSIONS Statins are still the cornerstone of drug therapy for patients with dyslipidemia; the rapid evaluation quantitative scoring table constructed in this study is comprehensive, systematic and operable. The evaluation process in this study can provide empirical references for other groups to exploring the standardized path and quality control mechanism of clinical comprehensive evaluation of drugs.
10.Study on integrated technology of producing area processing and decoction pieces processing of Curcuma longa
Mingyue AO ; Ying PENG ; Baohua DONG ; Yunxiu JIANG ; Yujiao LIAO ; Lingying YU ; Zhimin CHEN ; Changjiang HU
China Pharmacy 2022;33(2):172-178
OBJECTIVE To op timize the i ntegrated technology of producing area processing and decoction pieces processing of Curcuma longa (hereinafter refer to “integrated technology ”). METHODS The content of ethanol-soluble extract in C. longa was determined by hot leaching method ;the contents of curcumin ,demethoxycurcumin and bisdemethoxycurcumin were determined by high performance liquid chromatography. On the basis of identification of producing area processing technology , Using overall desirability (OD) value of the contents of ethanol-soluble extract , curcumin, demethoxycurcumin and bisdemethoxycurcumin as evaluation indexes ,moisture content ,slice thickness and drying temperature as factors ,the integrated technology of C. longa was optimized by single factor tests combined with central composite design-response surface method ,and the validation tests were conducted. At the same time ,prepared product was compared with traditional decoction pieces prepared according to 2020 edition of Chinese Pharmacopoeia (part Ⅰ). RESULTS The best integrated technology was that the fresh C. longa was boiled in boiling water for 5 min,dried at 50 ℃ to 40% water content ,cut into 2 mm thin slices ,and dried at 50 ℃ until moisture content not exceeding 15.0%. After validation ,The deviation between the average OD value (0.811 3,RSD=2.13%) and the predicted value (0.848 1)of the contents of ethanol-soluble extract ,curcumin,demethoxycurcumin and bisdemethoxycurcumin was 4.34%. OD value of the contents of ethanol-soluble extract ,curcumin,demethoxycurcumin and bisdemethoxycurcumin in decoction pieces prepared by integrated technology were all higher than those prepared by traditional technology. CONCLUSIONS The process optimized in this study is simple ,stable and feasible.

Result Analysis
Print
Save
E-mail